Cadence Pharmaceuticals Reports Second Quarter 2007 Financi...(S ...)
| HOME >> BIOLOGY >> TECHNOLOGY |
S
June 30, December 31,
2007 2006
(unaudited)
Assets
Current assets:
Cash and cash equivalents $66,922,662 $86,825,526
Restricted cash 1,981,849 347,849
Prepaid expenses and other
current assets 759,269 820,311
Total current assets 69,663,780 87,993,686
Property and equipment, net 4,716,313 3,558,618
Restricted cash 1,233,281 1,233,281
Other assets 444,832 536,042
Total assets $76,058,206 $93,321,627
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $5,040,081 $2,073,726
Accrued liabilities 10,959,172 7,378,750
Current portion of long-term debt 2,687,790 2,338,010
Total current liabilities 18,687,043 11,790,486
Deferred rent 1,347,069 1,460,109
Long-term debt, less current portion 3,279,753 4,661,990
Other long-term liabilities 22,048 -
Total stockholders' equity 52,722,293 75,409,042
Total liabilities and stockholders'
equity $76,058,206 $93,321,627
'/>"/>
SOURCE Cadence Pharmaceuticals, Inc. Copyright©2007 PR Newswire. |
Related biology technology :
1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |